ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.

REAL Letters in box
ICER Responds To Requests To Use More RWE In Assessments

More from Health Technology Assessment

More from Market Access